Acurx Pharmaceuticals (ACXP)
(Delayed Data from NSDQ)
$4.28 USD
-0.27 (-5.93%)
Updated Oct 6, 2025 04:00 PM ET
After-Market: $4.26 -0.02 (-0.47%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACXP 4.28 -0.27(-5.93%)
Will ACXP be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ACXP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACXP
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y
ACXP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
Other News for ACXP
ACXP forms Boomer Buy Setup on October 3
ACXP forms Non-ADX 1,2,3,4 Bearish on October 2
Bollinger Band Squeeze appears for ACXP after 7.23% move
Is ACXP signaling a buying opportunity? 20 Day Moving Average Support shows up after climbing 0.23%
ACXP: HC Wainwright & Co. Reiterates Buy Rating with $31 Price Target | ACXP Stock News